Live Breaking News & Updates on Complera eviplera

Stay informed with the latest breaking news from Complera eviplera on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Complera eviplera and stay connected to the pulse of your community

Gilead Sciences, Inc. (NASDAQ:GILD) Declares $0.77 Quarterly Dividend

Gilead Sciences, Inc. (NASDAQ:GILD) Declares $0.77 Quarterly Dividend
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states , Complera-eviplera , Merdad-parsey , Gilead-sciences-inc , Insider-transactions-at-gilead-sciences , Gilead-sciences-trading , Morgan-stanley , Nasdaq , Gilead-sciences , Dividend-history-for-gilead-sciences , News-ratings-for-gilead-sciences-daily , Get-free-report

Gilead Sciences (NASDAQ:GILD) Given New $85.00 Price Target at TD Cowen

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target decreased by TD Cowen from $90.00 to $85.00 in a report released on Friday, Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on GILD. Wells Fargo & Company decreased their price target […]

United-states , Canada , Complera-eviplera , Merdad-parsey , Wells-fargo-company , Securities-exchange-commission , Gilead-sciences-announces-dividend , Wealth-management-group , Gilead-sciences , Needham-company , Royal-bank , Analyst-recommendations-for-gilead-sciences

Argonautica Private Wealth Management Inc. Has $3.08 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Argonautica Private Wealth Management Inc. Has $3.08 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states , Canada , Complera-eviplera , Merdad-parsey , Gilead-sciences-price-performance , Royal-bank , Gilead-sciences-inc , Quarter-for-gilead-sciences , Nasdaq , Needham-company , Tompkins-financial-corp , Argonautica-private-wealth-management-inc

Gilead Sciences (NASDAQ:GILD) Receives "Hold" Rating from Needham & Company LLC

Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “hold” rating reiterated by Needham & Company LLC in a research note issued on Friday, Benzinga reports. Other equities research analysts have also issued research reports about the stock. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and […]

United-states , Merdad-parsey , Complera-eviplera , Gilead-sciences-inc , Securities-exchange-commission , Gilead-sciences-company-profile , Insider-transactions-at-gilead-sciences , Hermes-inc , Needham-company , Barclays , Gilead-sciences-stock-performance , Institutional-trading-of-gilead-sciences

Gilead Sciences (NASDAQ:GILD) PT Lowered to $74.00 at Royal Bank of Canada

Gilead Sciences (NASDAQ:GILD) PT Lowered to $74.00 at Royal Bank of Canada
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , United-states , Complera-eviplera , Merdad-parsey , Gilead-sciences , Tompkins-financial-corp , Hedge-funds-weigh-in-on-gilead-sciences , Needham-company , Wells-fargo-company , Gilead-sciences-stock , Gilead-sciences-company-profile , Wealth-management-group

Gilead Sciences (NASDAQ:GILD) Given New $74.00 Price Target at Royal Bank of Canada

Gilead Sciences (NASDAQ:GILD) Given New $74.00 Price Target at Royal Bank of Canada
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada , United-states , Merdad-parsey , Complera-eviplera , Royal-bank , Gilead-sciences-trading , Analyst-recommendations-for-gilead-sciences , Insider-transactions-at-gilead-sciences , News-ratings-for-gilead-sciences-daily , Gilead-sciences-inc , Hermes-inc , Securities-exchange-commission

Morgan Stanley Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $78.00

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price decreased by stock analysts at Morgan Stanley from $80.00 to $78.00 in a report released on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 18.88% from the […]

United-states , Complera-eviplera , Merdad-parsey , News-ratings-for-gilead-sciences-daily , Analyst-recommendations-for-gilead-sciences , Fortitude-family-office , Wealth-management-group , Gilead-sciences-trading , Insider-activity-at-gilead-sciences , Hedge-funds-weigh-in-on-gilead-sciences , Nasdaq , Gilead-sciences

Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $85.00 at TD Cowen

Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $85.00 at TD Cowen
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states , Complera-eviplera , Merdad-parsey , Barclays , Needham-company , Gilead-sciences-inc , Wells-fargo-company , Strategic-blueprint , Ballentine-partners , Koshinski-asset-management-inc , Analyst-recommendations-for-gilead-sciences , News-ratings-for-gilead-sciences-daily

Gilead Sciences (NASDAQ:GILD) PT Lowered to $78.00

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price dropped by equities researchers at Morgan Stanley from $80.00 to $78.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential […]

United-states , Wellington , New-zealand-general- , New-zealand , Complera-eviplera , Merdad-parsey , Gilead-sciences-inc , Wells-fargo-company , Manufacturers-life-insurance-company , Morgan-stanley , Gilead-sciences-company-profile , Gilead-sciences-price-performance

Meritage Portfolio Management Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Meritage Portfolio Management cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,558 shares of the biopharmaceutical company’s stock after selling 342 shares during the quarter. Meritage Portfolio Management’s holdings […]

United-states , Complera-eviplera , Merdad-parsey , Quarter-for-gilead-sciences , Gilead-sciences , Newbridge-financial-services-group-inc , Global-retirement-partners , Gilead-sciences-increases-dividend , Wells-fargo-company , Gilead-sciences-stock-performance , Insider-transactions-at-gilead-sciences , Wagner-wealth-management